Human papillomavirus infections in the oral mucosa

Journal of the American Dental Association

Volumn 142, Issue 8, 2011, Pages 905-914

  Rautava, Jaana ^a   Syrjänen, Stina ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Early detection of disease; Human papillomavirus; Oral cancer; Oral mucosa; Oral potentially malignant disorders; Risk; Transmission; Warts

Indexed keywords

EID: 80052082041     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2011.0297     Document Type: Article

References (71)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401(1):70-79.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324(1):17-27. (Pubitemid 38737395)
3. Chan SY, Delius H, Halpern AL, Bernard HU. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phytogeny, and taxonomy. J Virol 1995;69(5):3074-3083.
4. Muñoz N, Bosch FX, de Sanjosé S, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-527. (Pubitemid 36159887)
5. World Health Organization, International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. A Review of Human Carcinogens: Biological Agents. Lyon, France: International Agency for Research on Cancer; 2011:278-280. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; vol. 100, part B.
6. von Knebel Doeberitz M, Vinokurova S. Host factors in HPV-related carcinogenesis: cellular mechanisms controlling HPV infections. Arch Med Res 2009;4(K6):435-442.
7. Syrjänen K, Syrjänen S. Papillomavirus Infections in Human Pathology. New York City: Wiley; 2000.
8. Joyce JG, Tung JS, Przysiecki CT, et al. The LI major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 1999;274(9):5810-5822. (Pubitemid 29109237)
9. Giroglou T, Florin L, Schäfer F, Streeck RE, Sapp M. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 2001;75(3):1565-1570. (Pubitemid 32094716)
10. Yoon CS, Kim KD, Park SN, Cheong SW. alpha (6) Integrin is the main receptor of human papillomavirus type 16 VLP. Biochem Biophys Res Commun 2001;283(3):668-673.
11. Doorbar J, Griffin H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin Biol Ther 2007;7(5):677-689. (Pubitemid 46707190)
12. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89(2):213-228. (Pubitemid 35351540)
13. Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120(9):1756-1772.
14. Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochem Soc Trans 2007;35(part 6):1456-1460.
15. Syrjänen S. Current concepts on human papillomavirus infections in children. APMIS 2010:118(6-7):494-509.
16. Sarkola ME, Grénman SE, Rintala MA, Syrjänen KJ, Syrjänen SM. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand 2008;87(11):1181-1188.
17. Puranen M, Yliskoski M, Saarikoski S, Syrjänen K, Syrjänen S. Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am J Obstet Gynecol 1996;174(2):694-699. (Pubitemid 26070167)
18. Puranen MH, Yliskoski MH, Saarikoski SV, Syrjänen KJ, Syrjänen SM. Exposure of an infant to cervical human papillomavirus infection of the mother is common. Am J Obstet Gynecol 1997;176(5):1039-1045. (Pubitemid 27227516)
19. Rintala MA, Grénman S, Puranen MH, et al. Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. J Clin Microbiol 2005;43(1):376-381. (Pubitemid 40096326)
20. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009;199(9):1263-1269.
21. Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2010;39(1):166-181.
22. Rintala M, Grénman S, Puranen M, Syrjänen S. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol 2006;35(1):89-94. (Pubitemid 43020959)
23. Paaso AE, Louvanto K, Syrjänen KJ, et al. Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa (published online ahead of print June 1, 2011). J Gen Virol 2011. doi:10.1099/vir. 0.032011-0.
24. Kellokoski J, Syrjänen S, Kataja V, Yliskoski M, Syrjänen K. Acetowhite staining and its significance in diagnosis of oral mucosal lesions in women with genital HPV infections. J Oral Pathol Med 1990;19(6):278-283. (Pubitemid 20265038)
25. Brocklehurst P, Kujan O, Glenny AM, et al. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev 2010; (11): CD004150.
26. D'Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007;121(1):143-150. (Pubitemid 46753862)
27. Fakhry C, Sugar E, D'Souza G, Gillison M. Two-week versus sixmonth sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLoS One 2010;5(7):e11918.
28. Broutian TR, He X, Gillison ML. Automated high throughput DNA isolation for detection of human papillomavirus in oral rinse samples. J Clin Virol 2011;5(K4):270-275.
29. Rautava J, Luukkaa M, Heikinheimo K, Alin J, Grenman R, Happonen RP. Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival. Oral Oncol 2007;43(9):911-919. (Pubitemid 47369255)
30. Kellokoski J, Syrjänen S, Syrjänen K, Yliskoski M. Oral mucosal changes in women with genital HPV infection. J Oral Pathol Med 1990;19(3):142-148. (Pubitemid 20178566)
31. Syrjänen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol 2010;21(suppl 7):vii243-vii245.
32. Termine N, Panzarella V, Falaschini S, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 2008;19(10):1681-1690.
33. Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010;37(6):386-391.
34. Syrjänen S, Lodi G, von Bultzingslöwen I, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011;17(suppl 1):58-72.
35. Castro TM, Bussoloti Filho I, Nascimento VX, Xavier SD. HPV detection in the oral and genital mucosa of women with positive histopathological exam for genital HPV, by means of the PCR. Braz J Otorhinolaryngol 2009;75(2):167-171.
36. Termine N, Giovannelli L, Matranga D, et al. Low rate of oral human papillomavirus (HPV) infection in women screened for cervical HPV infection in Southern Italy: a cross-sectional study of 140 immunocompetent subjects. J Med Virol 2009;81(8):1438-1443.
37. Xavier SD, Bussoloti Filho I, de Carvalho JM, Castro TM, Framil VM, Syrjänen KJ. Prevalence of human papillomavirus (HPV) DNA in oral mucosa of men with anogenital HPV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108(5):732-737.
38. Louvanto K, Rintala MA, Syrjänen KJ, Grénman SE, Syrjänen SM. Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish Family HPV Study. J Infect Dis 2010;202(3):436-444.
39. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008;68(21):8813-8824.
40. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008;197(10):1436-1447. (Pubitemid 351706468)
41. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis 2002;186(4):462-469. (Pubitemid 34876254)
42. Ralston Howe E, Li Z, McGlennen RC, Hellerstedt WL, Downs LS Jr. Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol 2009;200(3):245.el-245.e7.
43. Louvanto K, Syrjänen KJ, Rintala MA, Grénman SE, Syrjänen SM. Genotype-specific clearance of genital human papillomavirus (HPV) infections among mothers in the Finnish family HPV study. J Clin Microbiol 2010;48(8):2665-2671.
44. Nielsen A, Kjaer SK, Munk C, Osier M, Iftner T. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 2010;82(4):616-623.
45. Castro TP, Bussoloti Filho I. Prevalence of human papillomavirus (HPV) in oral cavity and oropharynx. Braz J Otorhinolaryngol 2006;72(2):272-282. (Pubitemid 44313655)
46. Syrjanen S. Human papillomavirus infections and oral tumors. Med Microbiol Immunol 2003;192(3):123-128. (Pubitemid 37100654)
47. Lutzner M, Kuffer R, Blanchet-Bardon C, Croissant O. Different papillomaviruses as the causes of oral warts. Arch Dermatol 1982;118(6):393-399. (Pubitemid 12116646)
48. Beaudenon S, Praetorius F, Kremsdorf D, et al. A new type of human papillomavirus associated with oral focal epithelial hyperplasia. J Invest Dermatol 1987;88(2):130-135. (Pubitemid 17008990)
49. Cameron JE, Hagensee ME. Oral HPV complications in HIV-infected patients. Curr HIV/AIDS Rep 2008;5(3):126-131.
50. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(6):622-635. (Pubitemid 33601674)
51. Garcia de Souza F, Paradella T. Malignant potential of oral lichen planus: a meta-analysis. Rev Odonto Ciencia 2009;24(2):194-197.
52. Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983;12(6):418-424. (Pubitemid 14141093)
53. Herrero R, Castellsagué X, Pawlita M, et al; IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95(23):1772-1783. (Pubitemid 38008900)
54. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998;90(21):1626-1636. (Pubitemid 28523437)
55. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108(5):766-772. (Pubitemid 38076410)
56. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14(2):467-475. (Pubitemid 40270113)
57. Kingma DW, Allen RA, Moore W, et al. HPV genotype distribution in oral and oropharyngeal squamous cell carcinoma using seven in vitro amplification assays. Anticancer Res 2010;30(12):5099-5104.
58. Smith EM, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control 2010;21(9):1369-1378.
59. Mendelsohn AH, Lai CK, Shintaku IP, et al. Histopathologic findings of HPV and pl6 positive HNSCC. Laryngoscope 2010;120(9):1788-1794.
60. Zhao D, Xu QG, Chen XM, Fan MW. Human papillomavirus as an independent predictor in oral squamous cell cancer. Int J Oral Sci 2009;1(3):119-125.
61. Mehta V, Yu GP, Schantz SP. Population-based analysis of oral and oropharyngeal carcinoma: changing trends of histopathologic differentiation, survival and patient demographics. Laryngoscope 2010;120(11):2203-2212.
62. Pintos J, Black MJ, Sadeghi N, et al. Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol 2008;44(3):242-250. (Pubitemid 351249192)
63. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35.
64. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010;2:15.
65. Liang XH, Lewis J, Foote R, Smith D, Kademani D. Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. J Oral Maxillofac Surg 2008;66(9):1875-1880.
66. Simonato LE, Garcia JF, Sundefeld ML, Mattar NJ, Veronese LA, Miyahara GI. Detection of HPV in mouth floor squamous cell carcinoma and its correlation with clinicopathologic variables, risk factors and survival. J Oral Pathol Med 2008;37(10):593-598.
67. Rautava J, Kuuskoski J, Grenman R, Syrjanen S. HPV genotypes in 122 head and neck squamous cell carcinomas. Poster presented at: 26th International Papillomavirus Conference and Clinical Workshop; July 3-8, 2010; Montreal.
68. U. S. Food and Drug Administration. Vaccines, Blood and Biologics: Cervarix. "www.fda.gov/BiologicsBlocJVaccines/Vaccines/ApprovedProducts/ ucml86957.htm". Accessed June 29, 2011.
69. U. S. Food and Drug Administration. Vaccines, Blood and Biologics: Gardasil. "www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm094042.htm". Accessed June 29, 2011.
70. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011;11:13.
71. Brotherton J, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377(9783):2085-2092.